Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University of California, San Francisco |
---|---|
Information provided by: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00275249 |
The purpose of this study is to determine the extent to which analgesic tolerance develops in chronic pain patients who are either started on opioids or who receive an increase in pre-study opioid dose level and then observed during long-term (20 weeks) stable opioid therapy. In addition to clinical measures of relief of ongoing chronic pain, estimation of tolerance development will be supplemented by periodic assessment of the anti-nociceptive effects of opioids using the brief thermal sensitization model.
Condition | Intervention |
---|---|
Chronic Pain |
Drug: levorphanol |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Dose Comparison, Parallel Assignment |
Official Title: | Evolution of Analgesic Tolerance During Long Term Treatment of Chronic Pain With Opioids |
Estimated Enrollment: | 60 |
The purpose of this study is to determine the extent to which analgesic tolerance develops in chronic pain patients who are either started on opioids or who receive an increase in pre-study opioid dose level and then observed during long-term (20 weeks) stable opioid therapy. In addition to clinical measures of relief of ongoing chronic pain, estimation of tolerance development will be supplemented by periodic assessment of the anti-nociceptive effects of opioids using the brief thermal sensitization model.
Ages Eligible for Study: | 21 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
No special precautions are required for male subjects because levorphanol is an approved therapy for chronic pain.
Exclusion Criteria:
United States, California | |
UCSF Pain Clinical Research Center | |
San Francisco, California, United States, 94115 |
Principal Investigator: | Michael Rowbotham, MD | University of California, San Francisco |
Study ID Numbers: | H5612-23841 |
Study First Received: | January 9, 2006 |
Last Updated: | January 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00275249 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Chronic Pain |
Central Nervous System Depressants Narcotics Pain Peripheral Nervous System Agents |
Analgesics Levorphanol Analgesics, Opioid |
Sensory System Agents Therapeutic Uses Physiological Effects of Drugs Central Nervous System Depressants Narcotics Peripheral Nervous System Agents |
Analgesics Levorphanol Central Nervous System Agents Analgesics, Opioid Pharmacologic Actions |